Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Algeta’s Partner Bayer Submits Radium-223 for EU Marketing Authorization

Published: Monday, April 22, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Submission to trigger €50 million milestone payment to Algeta.

Algeta ASA has announced that Bayer has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for radium-223 dichloride (radium-223) for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

“The submission by Bayer of the MAA for radium-223 with the EMA is a significant landmark for Algeta. It carries us further towards realizing our vision of becoming a world class oncology company bringing novel targeted medicines to cancer patients,” said Andrew Kay, Algeta’s President & CEO.

Kay continued, “I would like to thank the teams at both Algeta and Bayer, which have worked diligently together, for delivering this major accomplishment. Under the terms of our 2009 Agreement, the first complete submission for marketing approval triggers a €50 million milestone payment to Algeta from Bayer. This submission also brings us another step closer to the royalties we are due from the launch of the product in Europe. Meanwhile, we look forward to the initiation of new trials evaluating the broader clinical potential of radium-223 for treating cancer patients with bone metastases.”

“This submission reflects our commitment to developing innovative cancer treatments for patients for whom only limited therapy options are available today,” said Kemal Malik, MD, Member of the Bayer HealthCare Executive Committee and Head of Global Development.

Malik continued, “With its novel mode of action and the proven survival benefit, radium-223 represents an innovation in the treatment of prostate cancer and is an important example of our growing oncology portfolio.”

The submission is based on data from the pivotal phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial, which was conducted by Algeta.

In the study, radium-223 significantly increased overall survival by 44 percent (HR=0.695, p=0.00007), resulting in a 30.5 percent reduction in the risk of death compared to placebo.

The median overall survival (OS) benefit in patients with radium-223 was 3.6 months, based on 14.9 months OS with radium-223 plus best standard of care (BSoC) vs. 11.3 months with placebo plus BSoC. These updated results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2012.

The most common hematologic adverse events for patients treated with radium-223 and best standard of care (BSoC) and compared to placebo and BSoC included anemia (31% vs. 31%), neutropenia (5% vs. 1%) and thrombocytopenia (12% vs. 6%).

With respect to Grade 3 and 4 adverse events, the most common events included anemia (13% vs. 13%), neutropenia (2% vs. 1%) and thrombocytopenia (6% vs. 2%).

The most common non-hematologic adverse events in patients treated with radium-223 and BSoC compared to placebo and BSoC included bone pain (50% vs. 62%), nausea (36% vs. 35%), diarrhea (25% vs. 15%) and vomiting (19% vs. 14%).

With respect to Grade 3 to 4 adverse events, the most common events included bone pain (21% vs. 26%).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Algeta Appoints Dr Andreas Menrad as CSO
Dr Menrad will be responsible for developing and executing the Company’s research strategy.
Monday, August 19, 2013
Algeta Celebrates the Opening of Commercial Production Facility for Xofigo®
Official opening of new facility at the Institute for Energy Technology (IFE) in Kjeller, Norway.
Friday, June 21, 2013
Algeta Announces First Sale of Xofigo® in the United States
First sale triggers EUR 50 million milestone payment from Bayer.
Thursday, May 30, 2013
Algeta: FDA Approves Xofigo (radium-223 dichloride)
Xofigo shown in a pivotal phase III trial to significantly improve overall survival.
Friday, May 17, 2013
Algeta Elects New Non-executive Members
Hilde Furberg and Paolo Pucci elected as new members of Algeta’s Board of Directors.
Friday, April 12, 2013
Algeta Initiates New Oncology Research Program to Conjugate Thorium-227 to Epratuzumab
CD22 is a well-validated target for hematological cancers.
Tuesday, January 29, 2013
Algeta and Ablynx Enter Into a Research Collaboration
Collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies®.
Thursday, November 22, 2012
Algeta and Sanofi Extend Research Collaboration
Collaboration is focused on evaluating thorium-conjugated tumor-targeting antibody.
Monday, October 15, 2012
New Analyses from Phase III ALSYMPCA Trial Presented at ESMO 2012
Radium-223 dichloride (Alpharadin) was significantly superior to placebo in health-related quality of life (QOL) measures.
Monday, October 01, 2012
Updated Phase III Data Confirm Overall Survival Benefit of Alpharadin in Men with CRPC
Submissions seeking marketing approval in US & Europe expected in 2H 2012.
Monday, June 04, 2012
Jeffrey W. Albers Appointed President of Algeta US
Mr. Albers will join Algeta’s executive management team and takes up his position immediately.
Tuesday, January 17, 2012
Algeta Awarded Grant to Develop Targeted Thorium Conjugates
Company has been awarded a NOK 10.5 million grant from the Research Council of Norway.
Tuesday, January 03, 2012
Algeta Appoints Mike Booth as Senior Vice President, Communications and Corporate Affairs
New role created to enhance Algeta's global corporate communications and investor relations activities.
Friday, December 30, 2011
Alpharadin Significantly Improves Overall Survival for CRPC Patients with Bone Metastases
First presentation of full ALSYMPCA phase III data as part of Presidential Session featuring Best and Late-Breaking Abstracts at 2011 EMCC.
Monday, October 10, 2011
Algeta Signs License with Affibody for Tumor-Targeting Molecules
Algeta gains access to two proprietary Affibody® molecules for use in cancer therapy.
Tuesday, August 30, 2011
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
How Cancer Spreads in the Body
Cancer cells appear to depend on an unusual survival mechanism to spread around the body, according to an early study led by Queen Mary University of London (QMUL).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
“Amazing Protein Diversity” Discovered in Maize
The genome of the corn plant – or maize, as it’s called almost everywhere except the US – “is a lot more exciting” than scientists have previously believed. So says the lead scientist in a new effort to analyze and annotate the depth of the plant’s genetic resources.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!